Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
Telix Pharmaceuticals has announced that a first patient has been dosed in a Phase II […]
EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501 for the Personalized Treatment of Depression (MDD)
EmbarkNeuro, a neuroscience-focused biotech company formerly known as Ancora Bio that was founded in 2021 […]
Vial Has Added NEXT Oncology, a Global Network of Phase I Cancer Research Centers, to their Preferred Site Network
Vial has added NEXT Oncology to their Preferred Site Network (PSN). Founded by renowned oncologist Dr. Anthony W. […]
CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy
Theragent, a cell therapy Contract Development and Manufacturing Organization (CDMO) focused on advancing next-generation cancer […]
Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for Duchenne Muscular Dystrophy Demonstrates Clinically Significant Functional and Biomarker Improvements
Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive 6-month results from […]
Advanced NanoTherapies' SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease
Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant […]
ViroCell Announces the Appointment of Susan B. Nichols as CBO
ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply […]
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined […]
ObvioHealth Introduces ObvioGo, a Next-Generation DCT Platform and Mobile Application Delivering Stronger Evidence
ObvioHealth, a pioneering virtual research organization (VRO), announces the launch of ObvioGo, a next-generation decentralized […]
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-Tumor Activity in Two Advanced Solid Tumors
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more